☰

Andrea Wang-Gillam, M.D., Ph.D. - Publications

Affiliations: 
2001 Washington Univ. School Medicine 
Area:
Pancreatic cancer
Website:
http://oncology.wustl.edu/people/faculty/Wang-Gillam/Wang-Gillam_Bio.html
Tree Info Similar researchers PubMed Report error

212 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Wang-Gillam A, Lim KH, McWilliams R, Suresh R, Lockhart AC, Brown A, Breden M, Belle JI, Herndon J, Bogner SJ, Pedersen K, Tan B, Boice N, Acharya A, Abdiannia M, et al. Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 29: 4698. PMID 37960920 DOI: 10.1158/1078-0432.CCR-23-2993  0.356
2023 Grierson PM, Suresh R, Tan B, Pedersen KS, Amin M, Park H, Trikalinos NA, Liu J, Boice N, Brown A, Bansod S, Wang-Gillam A, Lim KH. A pilot study of paricalcitol plus nanoliposomal irinotecan and 5-FU/LV in advanced pancreatic cancer patients after progression on gemcitabine-based therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37801295 DOI: 10.1158/1078-0432.CCR-23-1405  0.334
2023 Huffman BM, Basu Mallick A, Horick NK, Wang-Gillam A, Hosein PJ, Morse MA, Beg MS, Murphy JE, Mavroukakis S, Zaki A, Schlechter BL, Sanoff H, Manz C, Wolpin BM, Arlen P, et al. Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial. Jama Network Open. 6: e2249720. PMID 36602796 DOI: 10.1001/jamanetworkopen.2022.49720  0.338
2022 Grierson PM, Tan B, Pedersen KS, Park H, Suresh R, Amin MA, Trikalinos NA, Knoerzer D, Kreider B, Reddy A, Liu J, Der CJ, Wang-Gillam A, Lim KH. Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma. The Oncologist. PMID 36427020 DOI: 10.1093/oncolo/oyac237  0.346
2022 Wang-Gillam A, Lim KH, McWilliams R, Suresh R, Lockhart AC, Brown A, Breden M, Belle JI, Herndon J, Bogner SJ, Pedersen K, Tan B, Boice N, Acharya A, Abdiannia M, et al. Defactinib, pembrolizumab, and gemcitabine in patients with advanced treatment refractory pancreatic cancer: A phase I, dose escalation, and expansion study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36228156 DOI: 10.1158/1078-0432.CCR-22-0308  0.334
2022 Noel MS, Kim S, Hartley ML, Wong S, Picozzi VJ, Staszewski H, Kim DW, Van Tornout JM, Philip PA, Chung V, Ocean AJ, Wang-Gillam A. A randomized phase II study of SM-88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond. Cancer Medicine. PMID 35499204 DOI: 10.1002/cam4.4768  0.38
2021 Yarchoan M, Cope L, Ruggieri AN, Anders RA, Noonan AM, Goff LW, Goyal L, Lacy J, Li D, Patel AK, He AR, Abou-Alfa GK, Spencer K, Kim EJ, Davis SL, ... ... Wang-Gillam A, et al. Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. The Journal of Clinical Investigation. 131. PMID 34907910 DOI: 10.1172/JCI152670  0.373
2021 Amin M, Gao F, Terrero G, Picus J, Wang-Gillam A, Suresh R, Ma C, Tan B, Baggstrom M, Naughton MJ, Trull L, Belanger S, Fracasso PM, Lockhart AC. Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors. American Journal of Clinical Oncology. PMID 34310349 DOI: 10.1097/COC.0000000000000852  0.315
2021 Hassanzadeh C, Rudra S, Bommireddy A, Hawkins WG, Wang-Gillam A, Fields RC, Cai B, Park J, Green O, Roach M, Henke L, Kim H. Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation. Advances in Radiation Oncology. 6: 100506. PMID 33665480 DOI: 10.1016/J.Adro.2020.06.010  0.385
2021 Sohal DPS, Duong M, Ahmad SA, Gandhi NS, Beg MS, Wang-Gillam A, Wade JL, Chiorean EG, Guthrie KA, Lowy AM, Philip PA, Hochster HS. Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial. Jama Oncology. PMID 33475684 DOI: 10.1001/jamaoncol.2020.7328  0.309
2020 Wu AA, Bever KM, Ho WJ, Fertig EJ, Niu N, Zheng L, Parkinson RM, Durham JN, Onners BL, Ferguson A, Wilt C, Ko AH, Wang-Gillam A, Laheru DA, Anders RA, et al. A Phase 2 Study of Allogeneic GM-CSF Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32591464 DOI: 10.1158/1078-0432.Ccr-20-1025  0.408
2020 Dodhiawala PB, Khurana N, Zhang D, Cheng Y, Li L, Wei Q, Seehra K, Jiang H, Grierson PM, Wang-Gillam A, Lim KH. TPL2 enforces RAS-induced inflammatory signaling and is activated by point mutations. The Journal of Clinical Investigation. PMID 32573499 DOI: 10.1172/Jci137660  0.333
2020 Park H, Jin RU, Wang-Gillam A, Suresh R, Rigden C, Amin M, Tan BR, Pedersen KS, Lim KH, Trikalinos NA, Acharya A, Copsey ML, Navo KA, Morton AE, Gao F, et al. FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial. Jama Oncology. PMID 32469386 DOI: 10.1001/Jamaoncol.2020.2020  0.47
2020 O'Hara MH, Messersmith W, Kindler H, Zhang W, Pitou C, Szpurka AM, Wang D, Peng SB, Vangerow B, Khan AA, Koneru M, Wang-Gillam A. Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors. Journal of Pancreatic Cancer. 6: 21-31. PMID 32219196 DOI: 10.1089/pancan.2019.0018  0.36
2020 Grierson P, Teague A, Suresh R, Lim KH, Amin M, Pedersen K, Tan B, Huffman J, Boice N, Du L, Liu J, Lockhart AC, Wang-Gillam A. Phase Ib/II study combining tosedostat with capecitabine in patients with advanced pancreatic adenocarcinoma. Journal of Gastrointestinal Oncology. 11: 61-67. PMID 32175106 DOI: 10.21037/Jgo.2019.11.06  0.429
2020 Macarulla Mercadé T, Chen LT, Li CP, Siveke JT, Cunningham D, Bodoky G, Blanc JF, Lee KH, Dean A, Belanger B, Wang-Gillam A. Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial. Pancreas. 49: 62-75. PMID 31856081 DOI: 10.1097/Mpa.0000000000001455  0.497
2020 Grierson P, Wang-Gillam A, Park H, Pedersen K, Tan BR, Amin MA, Suresh R, Trikalinos N, Liu J. A pilot study of liposomal irinotecan plus 5-FU/LV combined with paricalcitol in patients with advanced pancreatic cancer progressed on gemcitabine-based therapy. Journal of Clinical Oncology. 38: TPS793-TPS793. DOI: 10.1200/Jco.2020.38.4_Suppl.Tps793  0.498
2020 Pant S, Chawla SP, Chung V, Del Priore G, Kim DW, Noel MS, Oberstein PE, Ocean AJ, Philip PA, Picozzi VJ, Simeone DM, Wang-Gillam A. Tyme-88-Panc Part 2: A randomized phase II/III of SM-88 with MPS as third-line in metastatic PDAC. Journal of Clinical Oncology. 38: TPS789-TPS789. DOI: 10.1200/Jco.2020.38.4_Suppl.Tps789  0.473
2020 Topping RP, Chiorean EG, Laheru D, Pishvaian MJ, Wang-Gillam A, Quill TA, Ko AH. Treatment patterns in pancreatic cancer: Differences between expert and community practitioners. Journal of Clinical Oncology. 38: e19207-e19207. DOI: 10.1200/Jco.2020.38.15_Suppl.E19207  0.325
2020 Jin R, Park H, Wang-Gillam A, Suresh R, Rigden CE, Amin MA, Tan BR, Pedersen K, Lim K, Trikalinos N, Acharya A, Copsey M, Navo K, Morton A, Gao F, et al. Final results of a phase II trial of first-line FOLFIRINOX for advanced gastroesophageal cancers. Journal of Clinical Oncology. 38: 4532-4532. DOI: 10.1200/Jco.2020.38.15_Suppl.4532  0.468
2020 Sohal D, Duong MT, Ahmad SA, Gandhi N, Beg MS, Wang-Gillam A, Wade JL, Chiorean EG, Guthrie KA, Lowy AM, Philip PA, Hochster HS. SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA). Journal of Clinical Oncology. 38: 4504-4504. DOI: 10.1200/Jco.2020.38.15_Suppl.4504  0.403
2020 Rasco DW, Bendell JC, Wang-Gillam A, Park W, O'Reilly EM, Zhou L, Galkin A, Carter LL, Nickle D, Li J, Ferguson B, Chaney MF, Dupont J, Messersmith WA. A phase I/II study of GB1275, a first-in-class oral CD11b modulator, alone, and combined with pembrolizumab in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (KEYNOTE-A36). Journal of Clinical Oncology. 38: 3085-3085. DOI: 10.1200/Jco.2020.38.15_Suppl.3085  0.468
2020 Wang-Gillam A, Rasco DW, Park W, O'Reilly E, Messersmith W, DeNardo DG, Gupta V, Zhou L, Galkin A, Slee D, Carter LL, Nickle D, Tran R, Li J, Ferguson B, et al. Abstract CT247: A phase 1/2 study of GB1275, a first-in-class CD11b modulator, as monotherapy and with an anti-PD-1 antibody in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (KEYNOTE-A36) Tumor Biology. DOI: 10.1158/1538-7445.Am2020-Ct247  0.372
2020 Park H, Otegbeye E, Kim H, Mutch M, Pedersen K, Amin M, Tan B, Trikalinos N, Lim K, Aranha O, Suresh R, Badiyan S, Silviera M, Henke L, Wise P, ... ... Wang-Gillam A, et al. Abstract CT234: Phase I study of epacadostat added to preoperative chemoradiation in patients with locally advanced rectal cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ct234  0.463
2020 Wang-Gillam A, McWilliams R, Lockhart AC, Tan BR, Suresh R, Lim K, Pedersen KS, Trikalinos N, Aranha O, Park H, Ratner L, Boice N, Denardo DG. Abstract CT118: Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer: Experiences of pancreatic ductal adenocarcinoma (PDAC) patients Tumor Biology. DOI: 10.1158/1538-7445.Am2020-Ct118  0.44
2020 Yarchoan M, Cope L, Anders RA, Noonan A, Goff LW, Goyal L, Lacy J, Li D, Patel A, He AR, Abou-Alfa G, Spencer K, Kim E, Xavier S, Ruggieri A, ... ... Wang-Gillam A, et al. Abstract CT043: A multicenter randomized phase 2 trial of atezolizumab as monotherapy or in combination with cobimetinib in biliary tract cancers (BTCs): A NCI Experimental Therapeutics Clinical Trials Network (ETCTN) study Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ct043  0.492
2020 Park H, Sanjeevaiah A, Suresh R, Mehta R, Trikalinos N, Bagegni N, Aranha O, Pedersen K, Nixon A, Jin R, Mills J, Fields R, Amin M, Lim K, Tan B, ... ... Wang-Gillam A, et al. P-131 Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Interim analysis of a phase II trial Annals of Oncology. 31. DOI: 10.1016/J.Annonc.2020.04.213  0.383
2019 Hu ZI, Bendell JC, Bullock A, LoConte NK, Hatoum H, Ritch P, Hool H, Leach JW, Sanchez J, Sohal DPS, Strickler J, Patel R, Wang-Gillam A, Firdaus I, Yu KH, et al. A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. Cancer Medicine. PMID 31347292 DOI: 10.1002/Cam4.2425  0.424
2019 Amin M, Desai M, Trinkaus K, Brown A, Wang-Gillam A, Tan B, Picus J, Sorscher S, Highkin M, Lears K, Lockhart AC. Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer. Journal of Gastrointestinal Oncology. 10: 412-420. PMID 31183190 DOI: 10.21037/Jgo.2019.02.01  0.36
2019 Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, Wang-Gillam A, Oberstein PE, Morse MA, Zeh H, Weekes CD, Reid T, Borazanci E, Crocenzi T, LoConte NK, Musher B, et al. A randomized Phase 2b study of GVAX pancreas and CRS-207 compared to chemotherapy in previously-treated metastatic pancreatic adenocarcinoma patients (ECLIPSE Study). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31126960 DOI: 10.1158/1078-0432.Ccr-18-2992  0.5
2019 Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali MA, Besselink MG, Boone BA, Chau I, Clarke S, Dillhoff M, El-Rayes BF, ... ... Wang-Gillam A, et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. Journal of the National Cancer Institute. PMID 31086963 DOI: 10.1093/Jnci/Djz073  0.453
2019 Macarulla T, Blanc JF, Wang-Gillam A, Chen LT, Siveke JT, Mirakhur B, Chen J, de Jong FA. Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial. Journal of Geriatric Oncology. PMID 30842038 DOI: 10.1016/J.Jgo.2019.02.011  0.465
2019 Wang-Gillam A, Hubner RA, Siveke JT, Von Hoff DD, Belanger B, de Jong FA, Mirakhur B, Chen LT. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. European Journal of Cancer (Oxford, England : 1990). 108: 78-87. PMID 30654298 DOI: 10.1016/J.Ejca.2018.12.007  0.447
2019 Grierson P, Oza A, Doyle M, Fields R, Hawkins W, Hammill C, Wang-Gillam A, Amin M, Pedersen K, Lim K, Morton A, Cordova C, Fowler K, Tan B, Chapman W. AB044. P-12. Phase 1 study of hepatic arterial infusion (HAI) therapy with floxuridine (FUDR) combined with systemic gemcitabine and oxaliplatin in patients with locally advanced intrahepatic cholangiocarcinoma (ICC) Hepatobiliary Surgery and Nutrition. 8: AB044-AB044. DOI: 10.21037/Hbsn.2019.Ab044  0.343
2019 Bagegni NA, Tan BR, Park H, Kraft K, Amin MA, Lim K, Morgensztern D, Pedersen K, Suresh R, Trikalinos N, Wang-Gillam A. A phase Ib trial of anti-VEGFR/PDGFR vorolanib combined with immune checkpoint inhibitors (CPIs) in solid tumors. Journal of Clinical Oncology. 37: TPS472-TPS472. DOI: 10.1200/Jco.2019.37.4_Suppl.Tps472  0.423
2019 Wang-Gillam A, O'Reilly EM, Bendell JC, Wainberg ZA, Borazanci EH, Bahary N, O'Hara MH, Beatty GL, Pant S, Cohen DJ, Leong S, Beg MS, Yu KH, Evans TJ, Seufferlein T, et al. A randomized phase II study of cabiralizumab (cabira) + nivolumab (nivo) ± chemotherapy (chemo) in advanced pancreatic ductal adenocarcinoma (PDAC). Journal of Clinical Oncology. 37: TPS465-TPS465. DOI: 10.1200/JCO.2019.37.4_SUPPL.TPS465  0.341
2019 Sohal D, McDonough S, Ahmad SA, Gandhi N, Beg MS, Wang-Gillam A, Wade JL, Guthrie KA, Lowy AM, Philip PA, Hochster HS. SWOG S1505: Initial findings on eligibility and neoadjuvant chemotherapy experience with mfolfirinox versus gemcitabine/nab-paclitaxel for resectable pancreatic adenocarcinoma. Journal of Clinical Oncology. 37: 414-414. DOI: 10.1200/Jco.2019.37.4_Suppl.414  0.453
2019 Noel MS, Wang-Gillam A, Ocean AJ, Del Priore G, Picozzi VJ. Feasibility of SM-88 in PC after multiple prior lines and ECOG < 2. Journal of Clinical Oncology. 37: 310-310. DOI: 10.1200/Jco.2019.37.4_Suppl.310  0.392
2019 Noel MS, Wang-Gillam A, Ocean AJ, Chawla SP, Del Priore G, Picozzi VJ. Phase II trial of SM-88 in patients with metastatic pancreatic cancer: Preliminary results of the first stage. Journal of Clinical Oncology. 37: 200-200. DOI: 10.1200/Jco.2019.37.4_Suppl.200  0.455
2019 Park H, Trikalinos N, Sanjeevaiah A, Pedersen K, Bagegni NA, Nixon AB, Huffman J, Tan BR, Suresh R, Lim K, Amin MA, Wang-Gillam A, Lockhart AC. Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma. Journal of Clinical Oncology. 37: TPS4150-TPS4150. DOI: 10.1200/Jco.2019.37.15_Suppl.Tps4150  0.473
2019 Huang J, Campian JL, Gao F, Johanns TM, Desjardins A, Wang-Gillam A, Rubin J. A phase I/II study of nivolumab plus or minus ipilimumab in combination with multifraction stereotactic radiosurgery for recurrent high-grade radiation-relapsed meningioma. Journal of Clinical Oncology. 37: TPS2073-TPS2073. DOI: 10.1200/Jco.2019.37.15_Suppl.Tps2073  0.456
2019 Noel MS, Wang-Gillam A, Ocean AJ, Chawla SP, Chung V, Del Priore G, Picozzi VJ. SM-88 therapy in high risk poor prognosis pancreatic cancer (PDAC). Journal of Clinical Oncology. 37: e15714-e15714. DOI: 10.1200/Jco.2019.37.15_Suppl.E15714  0.408
2019 Janku F, Gounder M, Pezeshki AM, Murthy R, Wang-Gillam A, Shepard D, Hong DS, Piha-Paul SA, Raina A, Leontovich AA, DeCrescenzo G, Kreider BL, Tung D, Varterasian M, Zhang HH, et al. Abstract A011: First-in-man clinical trial of intratumoral injection of Clostridiumnovyi-NT spores in patients with treatment-refractory advanced solid tumors: Safety, activity, and immune responses Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A011  0.423
2019 Conlon K, Leidner R, McNeel D, Gupta S, Wang-Gillam A, Waldmann TA, Pavlakis G, Dostalek M, Kurtulus S, Chowdhury NR, O'Keeffe J, Parikh NS, Thompson JA. Abstract CT082: Phase (Ph) I/Ib study of NIZ985 with and without spartalizumab (PDR001) in patients (pts) with metastatic/unresectable solid tumors Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Ct082  0.354
2019 Noel MS, Wang-Gillam A, Ocean AJ, Chawla S, Chung V, Korn R, Priore GD, Picozzi VJ. Abstract B16: CTC-based efficacy of SM-88 correlates with overall survival in advanced pancreatic cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Panca19-B16  0.497
2019 Ocean A, Noel M, Wang-Gillam A, Chawla S, Chung V, Pant S, Korn R, De Priore G, Picozzi V. Phase II monotherapy efficacy of cancer metabolism targeting SM-88 in heavily pre-treated PDAC patients Annals of Oncology. 30: v275. DOI: 10.1093/Annonc/Mdz247.046  0.431
2019 Wang-Gillam A, Yeckes-Rodin H, Kosmo M, Stanton T, Park H, Songhua F, Sauter N, Kania M. Phase I trial of fruquintinib in patients with advanced solid tumors: Results of the dose escalation phase Annals of Oncology. 30: v175-v176. DOI: 10.1093/Annonc/Mdz244.029  0.324
2019 Kim H, Olsen J, Wang-Gillam A, Green O, Fields R, Hammill C, Strasberg S, Doyle M, Hawkins W, Suresh R, Tan B, Pedersen K, Henke L, DeWees T, Chapman W, et al. Prospective Phase I Trial of Concurrent Full Dose Gemcitabine/Nab-paclitaxel and Ablative Radiation Therapy for Borderline and Locally Advanced Pancreatic Cancer International Journal of Radiation Oncology*Biology*Physics. 105: S209-S210. DOI: 10.1016/J.Ijrobp.2019.06.283  0.441
2019 Rudra S, Bommireddy A, Henke L, Wang-Gillam A, Kim H, Roach M. CA 19-9 Maintains Prognostic Value for Inoperable Pancreatic Cancer Patients Receiving Definitive Hypofractionated or Stereotactic Body Radiation Therapy International Journal of Radiation Oncology*Biology*Physics. 105: E244. DOI: 10.1016/J.Ijrobp.2019.06.1926  0.379
2018 Lee K, Bodoky G, Blanc J, Siveke J, Mercadé TM, Wang-Gillam A, Chen L, Mirakhur B, Chen J, de Jong F. Decreased appetite (DA) at baseline impacts prognosis in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: v42-v43. PMID 32177133 DOI: 10.1093/Annonc/Mdy151.152  0.364
2018 Lakatos G, Lee K, Siveke J, Blanc J, Mercadé TM, Dean A, Bodoky G, Mirakhur B, Chen J, Wang-Gillam A, Chen L, de Jong F. Prognostic value of baseline biliary stents on outcomes in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the NAPOLI-1 trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: v42. PMID 32177132 DOI: 10.1093/Annonc/Mdy151.150  0.378
2018 Mercadé TM, Wang-Gillam A, Chen L, Blanc J, Lee K, Bodoky G, Dean A, Chen J, Mirakhur B, Siveke J, de Jong F. The effect of best response to prior anticancer therapy on efficacy outcomes in the NAPOLI-1 trial of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: v42. PMID 32177131 DOI: 10.1093/Annonc/Mdy151.151  0.421
2018 Mercadé TM, Wang-Gillam A, Chen L, Blanc J, Lee K, Bodoky G, Dean A, Siveke J, Mirakhur B, Chen J, de Jong F. Prognostic effect of primary tumor location in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: v41-v42. PMID 32177128 DOI: 10.1093/Annonc/Mdy151.149  0.392
2018 Mercadé TM, Lee K, Lakatos G, Wang-Gillam A, Chen L, Mirakhur B, De Jong F. Selected subgroup analyses of liposomal irinotecan (nal-IRI) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the global NAPOLI-1 phase III trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: v101. PMID 32176984 DOI: 10.1093/Annonc/Mdy149.003  0.431
2018 Hubner RA, Cubillo A, Blanc JF, Melisi D, Von Hoff DD, Wang-Gillam A, Chen LT, Becker C, Mamlouk K, Belanger B, Yang Y, de Jong FA, Siveke JT. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin. European Journal of Cancer (Oxford, England : 1990). 106: 24-33. PMID 30458340 DOI: 10.1016/J.Ejca.2018.09.029  0.424
2018 Chen LT, Siveke JT, Wang-Gillam A, Li CP, Bodoky G, Dean AP, Shan YS, Jameson GS, Macarulla T, Lee KH, Cunningham D, Blanc JF, Chiu CF, Schwartsmann G, Braiteh FS, et al. Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial. European Journal of Cancer (Oxford, England : 1990). 105: 71-78. PMID 30414528 DOI: 10.1016/J.Ejca.2018.09.010  0.459
2018 Jiang H, Xu M, Li L, Grierson P, Dodhiawala P, Highkin M, Zhang D, Li Q, Wang-Gillam A, Lim KH. Concurrent HER or PI3K Inhibition Potentiates the Anti-tumor Effect of ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models. Molecular Cancer Therapeutics. PMID 30065098 DOI: 10.1158/1535-7163.Mct-17-1142  0.398
2018 Wolff RA, Wang-Gillam A, Alvarez H, Tiriac H, Engle D, Hou S, Groff AF, San Lucas A, Bernard V, Allenson K, Castillo J, Kim D, Mulu F, Huang J, Stephens B, et al. Dynamic changes during the treatment of pancreatic cancer. Oncotarget. 9: 14764-14790. PMID 29599906 DOI: 10.18632/Oncotarget.24483  0.396
2018 Lang GD, Mullady DK, Early DS, Hollander T, Edmundowicz SA, Murad FM, Strasberg SM, Fields RC, Hawkins WG, Doyle MB, Chapman WC, Wang-Gillam A, Kushnir VM. Utility of Endoscopic Ultrasound in Evaluating Local Recurrence After Surgery for Pancreatic Cancer. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 29505906 DOI: 10.1016/J.Cgh.2018.02.031  0.387
2018 Zhang D, Li L, Jiang H, Li Q, Wang-Gillam A, Yu J, Head R, Liu J, Ruzinova MB, Lim KH. Tumor-stroma IL-1β-IRAK4 feedforward circuitry drives tumor fibrosis, chemoresistance, and poor prognosis in pancreatic cancer. Cancer Research. PMID 29363544 DOI: 10.1158/0008-5472.Can-17-1366  0.357
2018 Linehan D, Noel MS, Hezel AF, Wang-Gillam A, Eskens F, Sleijfer S, Desar IM, Erdkamp F, Wilmink J, Diehl J, Potarca A, Zhao N, Miao S, Deng J, Hillson J, et al. Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: Correlation with blood monocyte counts. Journal of Clinical Oncology. 36: 92-92. DOI: 10.1200/Jco.2018.36.5_Suppl.92  0.45
2018 Park H, Wang-Gillam A, Suresh R, Rigden CE, Amin MA, Tan BR, Pedersen K, Lim K, Trikalinos N, Navo K, Morton A, Schrumpf L, Marquez S, Trinkaus K, Lockhart AC. A phase II trial of first-line FOLFIRINOX for patients with advanced gastroesophageal adenocarcinoma. Journal of Clinical Oncology. 36: 89-89. DOI: 10.1200/Jco.2018.36.4_Suppl.89  0.462
2018 Oza A, Grierson P, Glasgow S, Pedersen K, Barman S, Westbrook T, Mutch MG, Wang-Gillam A, Suresh R, Morton A, Marquez S, Fleshman JW, Tan BR. A phase I dose-escalation trial of intraperitoneal oxaliplatin with systemic capecitabine and bevacizumab following cytoreduction in patients with peritoneal carcinomatosis from appendiceal or colorectal cancer. Journal of Clinical Oncology. 36: 746-746. DOI: 10.1200/Jco.2018.36.4_Suppl.746  0.432
2018 Siveke JT, Hubner R, Macarulla TM, Wang-Gillam A, Dean AP, Blanc J, Cunningham D, Mirakhur B, Belanger B, de Jong FA, Chen L. Subgroup analysis by measurable metastatic lesion (ML) number and selected lesion locations (LL) at baseline (BL) in NAPOLI-1: A phase III study of liposomal irinotecan (nal-IRI)±5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy. Journal of Clinical Oncology. 36: 460-460. DOI: 10.1200/Jco.2018.36.4_Suppl.460  0.349
2018 Wang-Gillam A, Hubner R, Mirakhur B, de Jong FA, Belanger B, Chen L. Nomogram for predicting overall survival (OS) in patients (pts) treated with liposomal irinotecan (nal-IRI) ± 5-fluorouracil/leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy in NAPOLI-1. Journal of Clinical Oncology. 36: 459-459. DOI: 10.1200/Jco.2018.36.4_Suppl.459  0.386
2018 Grierson P, Oza A, Doyle MM, Fowler K, Fields R, Hawkins WG, Hammill C, Wang-Gillam A, Amin MA, Pedersen K, Lim K, Morton A, Cordova C, Tan BR, Chapman WC. Phase I study of hepatic arterial infusion (HAI) therapy with floxuridine (FUDR) combined with systemic gemcitabine and oxaliplatin in patients with locally advanced intrahepatic cholangiocarcinoma (ICC). Journal of Clinical Oncology. 36: 417-417. DOI: 10.1200/Jco.2018.36.4_Suppl.417  0.357
2018 Macarulla TM, Hubner R, Blanc J, Wang-Gillam A, Li C, Bodoky G, Dean AP, Yanshen S, Jameson GS, Lee K, Chiu C, Schwartsmann G, Braiteh FS, Cunningham D, Chen L, et al. Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal-IRI)±5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based (gem) therapy. Journal of Clinical Oncology. 36: 410-410. DOI: 10.1200/Jco.2018.36.4_Suppl.410  0.387
2018 Wang-Gillam A, Hubner R, Mirakhur B, de Jong FA, Belanger B, Chen L. Dose modifications of liposomal irinotecan (nal-IRI) + 5-fluorouracil/leucovorin (5-FU/LV) in NAPOLI-1: Impact on efficacy. Journal of Clinical Oncology. 36: 388-388. DOI: 10.1200/Jco.2018.36.4_Suppl.388  0.391
2018 Macarulla TM, Siveke JT, Dean AP, Hubner R, Blanc J, Cunningham D, Chen L, Mirakhur B, Chen J, de Jong FA, Wang-Gillam A. Subgroup analysis by baseline pain intensity (BPI) and analgesic use (BAU) in NAPOLI-1: A phase III study of liposomal irinotecan (nal IRI)±5-fluorouracil/ leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy. Journal of Clinical Oncology. 36: 379-379. DOI: 10.1200/Jco.2018.36.4_Suppl.379  0.357
2018 Barzi A, Raymond V, Wang-Gillam A, Lanman RB. Cell free circulating tumor DNA ERBB2 amplifications are targetable in patients with pancreatic ductal adenocarcinoma. Journal of Clinical Oncology. 36: 282-282. DOI: 10.1200/Jco.2018.36.4_Suppl.282  0.367
2018 Wang-Gillam A, Hubner R, Mirakhur B, de Jong F, Belanger B, Chen L. A survival prediction nomogram for liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy. Journal of Clinical Oncology. 36: e16204-e16204. DOI: 10.1200/Jco.2018.36.15_Suppl.E16204  0.427
2018 Bahary N, Wang-Gillam A, Haraldsdottir S, Somer BG, Lee JS, O'Rourke MA, Nayak-Kapoor A, Beatty GL, Liu M, Delman D, Rossi GR, Kennedy EP, Vahanian NN, Link CJ, Garrido-Laguna I. Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of patients with metastatic pancreas cancer. Journal of Clinical Oncology. 36: 4015-4015. DOI: 10.1200/Jco.2018.36.15_Suppl.4015  0.423
2018 Wang-Gillam A, Lockhart AC, Tan BR, Suresh R, Lim K, Ratner L, DeNardo DG. Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer. Journal of Clinical Oncology. 36: 2561-2561. DOI: 10.1200/Jco.2018.36.15_Suppl.2561  0.427
2018 Zhang D, Li L, Jiang H, Wang-Gillam A, Yu J, Head R, Liu J, Ruzinova MB, Lim K. Abstract 995: Tumor-stroma IL-1β-IRAK4 feedforward circuitry drives tumor fibrosis, chemo-resistance and is associated with poor prognosis in pancreatic cancer Tumor Biology. DOI: 10.1158/1538-7445.Am2018-995  0.339
2018 Jiang H, Xu M, Li L, Highkin M, Zhang D, Li Q, Wang-Gillam A, Lim K. Abstract 2375: Concurrent HER or PI3K inhibition potentiates the anti-tumor effect of ERK inhibitor BVD-523 (ulixertinib) in preclinical pancreatic cancer models Cancer Research. 78: 2375-2375. DOI: 10.1158/1538-7445.Am2018-2375  0.42
2018 Chen L, Macarulla Mercadé T, Lee K, Lakatos G, Wang-Gillam A, Mirakhur B, de Jong F. Liposomal irinotecan (nal-IRI) plus 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) progressing on gemcitabine-based treatment: Further subgroup analyses of the pivotal NAPOLI-1 study Annals of Oncology. 29: ix63. DOI: 10.1093/Annonc/Mdy432.051  0.433
2017 Blanc JF, Hubner R, Li CP, Wang-Gillam A, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Chiu CF, Schwartsmann G, Braiteh F, Von Hoff D, et al. Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI±5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28: iii7. PMID 32135989 DOI: 10.1093/Annonc/Mdx263.017  0.427
2017 Chen LT, Wang-Gillam A, Shan YS, Macarulla T, Blanc JF, Hubner R, Chiu CF, Schwartsmann G, Siveke J, Marc PJ, Belanger B, de Jong F, Mamlouk K, Von Hoff D. CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28: iii6-iii7. PMID 32135959 DOI: 10.1093/Annonc/Mdx263.016  0.396
2017 Regenbogen T, Chen L, Trinkaus K, Wang-Gillam A, Tan BR, Amin M, Pedersen KS, Park H, Suresh R, Lim KH, Ratchford E, Brown A, Lockhart AC. Pacritinib to inhibit JAK/STAT signaling in refractory metastatic colon and rectal cancer. Journal of Gastrointestinal Oncology. 8: 985-989. PMID 29299358 DOI: 10.21037/Jgo.2017.08.16  0.41
2017 Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, et al. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. Cancer Discovery. PMID 29247021 DOI: 10.1158/2159-8290.Cd-17-1119  0.41
2017 Hingorani SR, Zheng L, Bullock AJ, Seery TE, Harris WP, Sigal DS, Braiteh F, Ritch PS, Zalupski MM, Bahary N, Oberstein PE, Wang-Gillam A, Wu W, Chondros D, Jiang P, et al. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017749564. PMID 29232172 DOI: 10.1200/Jco.2017.74.9564  0.423
2017 Du L, Wang-Gillam A. Trends in Neoadjuvant Approaches in Pancreatic Cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 15: 1070-1077. PMID 28784867 DOI: 10.6004/Jnccn.2017.0134  0.478
2017 Du L, Che Z, Wang-Gillam A. Promising therapeutics of gastrointestinal cancers in clinical trials. Journal of Gastrointestinal Oncology. 8: 524-533. PMID 28736639 DOI: 10.21037/Jgo.2017.01.08  0.369
2017 Wang-Gillam A, Lim KH. Entering the molecular era of gastrointestinal oncology: current updates and challenges. Journal of Gastrointestinal Oncology. 8: 377-378. PMID 28736625 DOI: 10.21037/Jgo.2017.05.02  0.336
2017 Lim KH, Langley E, Gao F, Luo J, Li L, Meyer G, Kim P, Singh S, Kushnir VM, Early DS, Mullady DK, Edmundowicz SA, Wani S, Murad FM, Cao D, ... ... Wang-Gillam A, et al. A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma. Oncotarget. 8: 24250-24261. PMID 28445954 DOI: 10.18632/Oncotarget.15653  0.369
2017 Pelzer U, Blanc JF, Melisi D, Cubillo A, Von Hoff DD, Wang-Gillam A, Chen LT, Siveke JT, Wan Y, Solem CT, Botteman MF, Yang Y, de Jong FA, Hubner RA. Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. British Journal of Cancer. PMID 28350787 DOI: 10.1038/Bjc.2017.67  0.459
2017 Sohal D, McDonough SL, Ahmad SA, Gandhi N, Beg MS, Wang-Gillam A, Guthrie KA, Lowy AM, Philip PA, Hochster HS. SWOG S1505: A randomized phase II study of perioperative mFOLFIRINOX vs. gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adenocarcinom. Journal of Clinical Oncology. 35: TPS508-TPS508. DOI: 10.1200/Jco.2017.35.4_Suppl.Tps508  0.463
2017 Wang-Gillam A, Lockhart AC, Tan BR, Suresh R, Singh PP, Lim K, Pedersen K, Amin MA, Hawkins WG, DeNardo DG. Phase I study of defactinib combined with pembrolizumab and gemcitabine in advanced cancer. Journal of Clinical Oncology. 35: TPS505-TPS505. DOI: 10.1200/Jco.2017.35.4_Suppl.Tps505  0.481
2017 Wang-Gillam A, Du L, Teague AS, Suresh R, Lim K, Amin MA, Pedersen K, Tan BR, Huffman J, Lockhart AC. A phase I/II study combining tosedostat with capecitabine in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). Journal of Clinical Oncology. 35: 410-410. DOI: 10.1200/Jco.2017.35.4_Suppl.410  0.466
2017 Le DT, Ko AH, Wainberg ZA, Picozzi VJ, Kindler HL, Wang-Gillam A, Oberstein PE, Morse M, Zeh H, Weekes CD, Reid TR, Murphy A, McDougall K, Whiting CC, Nair N, et al. Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study). Journal of Clinical Oncology. 35: 345-345. DOI: 10.1200/Jco.2017.35.4_Suppl.345  0.455
2017 Chen L, Wang-Gillam A, Yanshen S, Macarulla T, Blanc J, Hubner R, Chiu C, Schwartsmann G, Siveke JT, Pipas JM, Belanger B, de Jong F, Mamlouk K, Von Hoff DD. Efficacy and safety of liposomal irinotecan (nal-IRI) + 5-fluorouracil and leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who previously received gemcitabine (gem)-based therapy: Post-hoc analysis of the NAPOLI-1 trial. Journal of Clinical Oncology. 35: 303-303. DOI: 10.1200/Jco.2017.35.4_Suppl.303  0.399
2017 Wang-Gillam A, Li C, Bodoky G, Dean A, Lee K, Cunningham D, Hubner R, Siveke JT, Braiteh FS, Pipas JM, Belanger B, de Jong F, Mody PD, Chen L, Von Hoff DD. Characteristics of long-term survivors in a randomized phase III trial (NAPOLI-1) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398) + 5-FU/LV. Journal of Clinical Oncology. 35: 293-293. DOI: 10.1200/Jco.2017.35.4_Suppl.293  0.409
2017 O'Reilly EM, Sahai V, Bendell JC, Bullock AJ, LoConte NK, Hatoum H, Ritch PS, Hool H, Leach JW, Sanchez J, Sohal D, Strickler JH, Patel R, Wang-Gillam A, Firdaus I, et al. Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC). Journal of Clinical Oncology. 35: 279-279. DOI: 10.1200/Jco.2017.35.4_Suppl.279  0.437
2017 Noel MS, Hezel AF, Linehan D, Wang-Gillam A, Eskens F, Sleijfer S, Desar I, Erdkamp F, Wilmink J, Diehl J, Potarca A, Zhao N, Deng J, Lohr L, Miao S, et al. Orally administered CCR2 selective inhibitor CCX872-b clinical trial in pancreatic cancer. Journal of Clinical Oncology. 35: 276-276. DOI: 10.1200/Jco.2017.35.4_Suppl.276  0.463
2017 Wang-Gillam A, Chen L, Li C, Bodoky G, Dean A, Lee K, Cunningham D, Hubner R, Braiteh FS, Pipas JM, Belanger B, de Jong FA, Mody PD, Von Hoff DD, Siveke JT. The prognostic value of baseline neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for predicting clinical outcome in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398) + 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV. Journal of Clinical Oncology. 35: e15795-e15795. DOI: 10.1200/Jco.2017.35.15_Suppl.E15795  0.398
2017 Macarulla TM, Siveke JT, Wang-Gillam A, Li C, Bodoky G, Dean AP, Yanshen S, Jameson GS, Lee K, Blanc J, Chiu C, Schwartsmann G, Braiteh FS, Cunningham D, Chen L, et al. Subgroup analysis by prior lines of metastatic therapy (mtx) in NAPOLI-1: A global, randomized phase 3 study of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV), vs. 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who have progressed following gemcitabine-based therapy. Journal of Clinical Oncology. 35: 4127-4127. DOI: 10.1200/Jco.2017.35.15_Suppl.4127  0.43
2017 Li BT, Janku F, Patel MR, Sullivan RJ, Flaherty K, Buchbinder EI, Lacouture ME, Varghese AM, Wong DJL, Sznol M, Sosman JA, Keedy VL, Wang-Gillam A, Ribas A, Tolcher AW, et al. First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study. Journal of Clinical Oncology. 35: 2508-2508. DOI: 10.1200/Jco.2017.35.15_Suppl.2508  0.44
2017 Sullivan RJ, Janku F, Li BT, Wong D, Sosman J, Keedy V, Buchbinder E, Tolcher A, Varghese A, Hyman DM, Flaherty KT, Ribas A, Carvajal R, Wang-Gillam A, Kluger H, et al. Abstract CT003: Activity of the ERK1/2 inhibitor ulixertinib (BVD-523) in patients withBRAFandNRASmutant melanoma Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct003  0.429
2017 Hubner R, Chen L, Li C, Bodoky G, Dean A, Lee K, Cunningham D, Siveke J, Braiteh F, de Jong F, Belanger B, Walls R, Mody P, von Hoff D, Wang-Gillam A. Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI) + 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone Annals of Oncology. 28: v253. DOI: 10.1093/Annonc/Mdx369.124  0.385
2016 Chung V, McDonough S, Philip PA, Cardin D, Wang-Gillam A, Hui L, Tejani MA, Seery TE, Dy IA, Al Baghdadi T, Hendifar AE, Doyle LA, Lowy AM, Guthrie KA, Blanke CD, et al. Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. Jama Oncology. PMID 27978579 DOI: 10.1001/Jamaoncol.2016.5383  0.474
2016 Wang-Gillam A, Von Hoff D, Siveke J, Hubner R, Belanger B, Pipas JM, Chen LT. Nanoliposomal Irinotecan in the Clinical Practice Guideline for Metastatic Pancreatic Cancer: Applicability to Clinical Situations. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016701607. PMID 27918719 DOI: 10.1200/Jco.2016.70.1607  0.338
2016 Brauer DG, Strand MS, Sanford DE, Kushnir VM, Lim KH, Mullady DK, Tan BR, Wang-Gillam A, Morton AE, Ruzinova MB, Parikh PJ, Narra VR, Fowler KJ, Doyle MB, Chapman WC, et al. Utility of a multidisciplinary tumor board in the management of pancreatic and upper gastrointestinal diseases: an observational study. Hpb : the Official Journal of the International Hepato Pancreato Biliary Association. PMID 27916436 DOI: 10.1016/J.Hpb.2016.11.002  0.338
2016 Michel LS, Dyroff S, Brooks FJ, Spayd KJ, Lim S, Engle JT, Phillips S, Tan B, Wang-Gillam A, Bognar C, Chu W, Zhou D, Mach RH, Laforest R, Chen DL. PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies. Radiology. 161929. PMID 27841728 DOI: 10.1148/Radiol.2016161929  0.304
2016 Atkins JJ, Fiala MA, Wang-Gillam A, Wildes TM. Racial Disparities in the Outcomes of Patients With Stage IV Pancreatic Adenocarcinoma Are Mediated by Chemotherapy Utilization. Pancreas. 45: e33-4. PMID 27400157 DOI: 10.1097/Mpa.0000000000000618  0.369
2016 Jiang H, Hegde S, Knolhoff BL, Zhu Y, Herndon JM, Meyer MA, Nywening TM, Hawkins WG, Shapiro IM, Weaver DT, Pachter JA, Wang-Gillam A, DeNardo DG. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nature Medicine. PMID 27376576 DOI: 10.1038/Nm.4123  0.375
2016 Chen LT, Wang-Gillam A, Von Hoff DD, Bayever E, Belanger B. Nanoliposomal irinotecan in metastatic pancreatic cancer - Authors' reply. Lancet (London, England). 387: 1997. PMID 27203770 DOI: 10.1016/S0140-6736(16)30365-8  0.4
2016 Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, Moorcraft SY, Conroy T, Hohla F, Allen P, Taieb J, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. The Lancet. Oncology. PMID 27160474 DOI: 10.1016/S1470-2045(16)00172-8  0.451
2016 Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA, Yano M, Fowler KJ, Lockhart AC, Suresh R, Tan BR, Lim KH, et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. The Lancet. Oncology. PMID 27055731 DOI: 10.1016/S1470-2045(16)00078-4  0.466
2016 D'Amico L, Mahajan S, Capietto AH, Yang Z, Zamani A, Ricci B, Bumpass DB, Meyer M, Su X, Wang-Gillam A, Weilbaecher K, Stewart SA, DeNardo DG, Faccio R. Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer. The Journal of Experimental Medicine. PMID 27045006 DOI: 10.1084/Jem.20150950  0.314
2016 Saif Ur Rehman S, Lim K, Wang-Gillam A. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer. Expert Review of Anticancer Therapy. PMID 27043737 DOI: 10.1080/14737140.2016.1174581  0.472
2016 Olsen JR, Parikh PJ, DeWees TA, Olsen L, Hawkins WG, Strasberg SM, Lim K, Singh PP, Suresh R, Tan BR, Ratner L, Fields RC, Amin MA, Wang-Gillam A. Prospective phase I study of nab-paclitaxel plus gemcitabine with concurrent MR-guided IMRT in patients with locally advanced or borderline resectable pancreatic cancer. Journal of Clinical Oncology. 34: TPS480-TPS480. DOI: 10.1200/Jco.2016.34.4_Suppl.Tps480  0.462
2016 Teague AS, Amin MA, Lim K, Lockhart AC, Masood A, Picus J, Singh PP, Suresh R, Tan BR, Wang-Gillam A. A phase I/II study combining tosedostat with capecitabine in patients with metastatic pancreatic adenocarcinoma. Journal of Clinical Oncology. 34: TPS471-TPS471. DOI: 10.1200/Jco.2016.34.4_Suppl.Tps471  0.477
2016 Amin MA, Wang-Gillam A, Tan BR, Suresh R, Picus J, Singh PP, Lim K, Masood A, Lockhart AC. Impact of comorbidities using Adult Comorbidity Evaluation-27 (ACE-27) score on survival in stage II colon cancer: Age, TNM staging, and pathological high risk-disease. Journal of Clinical Oncology. 34: 659-659. DOI: 10.1200/Jco.2016.34.4_Suppl.659  0.352
2016 Bahary N, Garrido-Laguna I, Wang-Gillam A, Nyak-Kapoor A, Kennedy E, Vahanian NN, Link CJ. Results of the phase Ib portion of a phase I/II trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreatic cancer. Journal of Clinical Oncology. 34: 452-452. DOI: 10.1200/Jco.2016.34.4_Suppl.452  0.503
2016 Hingorani SR, Harris WP, Seery TE, Zheng L, Sigal D, Hendifar AE, Braiteh FS, Zalupski M, Baron AD, Bahary N, Wang-Gillam A, LoConte NK, Springett GM, Ritch PS, Hezel AF, et al. Interim results of a randomized phase II study of PEGPH20 added to nab-paclitaxel/gemcitabine in patients with stage IV previously untreated pancreatic cancer. Journal of Clinical Oncology. 34: 439-439. DOI: 10.1200/Jco.2016.34.4_Suppl.439  0.414
2016 Chen L, Siveke JT, Wang-Gillam A, Hubner R, Pant S, Dragovich T, Chung VM, Chang DZ, Ross PJ, Cooray P, Tebbutt NC, Franke FA, Belanger B, Dhindsa N, Jong FD, et al. Effect of baseline carbohydrate antigen 19-9 (CA19-9) level on overall survival (OS) in NAPOLI-1 trial: A phase III study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy. Journal of Clinical Oncology. 34: 425-425. DOI: 10.1200/Jco.2016.34.4_Suppl.425  0.397
2016 Wang-Gillam A, Li C, Bodoky G, Dean A, Shan Y, Jameson GS, Macarulla T, Lee K, Cunningham D, Blanc J, Hubner R, Chiu C, Schwartsmann G, Siveke JT, Braiteh FS, et al. Updated overall survival analysis of NAPOLI-1: Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy. Journal of Clinical Oncology. 34: 417-417. DOI: 10.1200/Jco.2016.34.4_Suppl.417  0.401
2016 Brauer DG, Strand MS, Sanford DE, Doyle MM, Murad F, Mullady D, Kushnir VM, Ruzinova M, Olsen JR, Parikh PJ, Lim K, Tan BR, Edmundowicz SA, Wang-Gillam A, Hawkins WG, et al. Utility of a multidisciplinary tumor board in the management of pancreatic diseases. Journal of Clinical Oncology. 34: 319-319. DOI: 10.1200/Jco.2016.34.4_Suppl.319  0.373
2016 Wang-Gillam A, Noel MS, Sleijfer S, Jung H, Lohr L, Zhao N, Miao S, Potarca A, Charo I, Bekker P, Schall TJ. The inhibition of CCR2 to modify the microenvironment in pancreatic cancer mouse model and to support the profiling of the CCR2 inhibitor CCX872-B in patients. Journal of Clinical Oncology. 34: e15743-e15743. DOI: 10.1200/Jco.2016.34.15_Suppl.E15743  0.342
2016 Pelzer U, Blanc J, Melisi D, Cubillo A, Von Hoff DD, Wang-Gillam A, Chen L, Siveke JT, Wan Y, Solem CT, Botteman M, Yang Y, de Jong F, Hubner R. Quality-adjusted time without symptoms or toxicity (Q-TWiST) of nanoliposomal irinotecan (nal-IRI; MM-398) plus 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma (mPAC) patients (pts) previously treated with gemcitabine-based therapy. Journal of Clinical Oncology. 34: e15732-e15732. DOI: 10.1200/Jco.2016.34.15_Suppl.E15732  0.451
2016 Borad MJ, Kwak EL, Wang-Gillam A, Ibrahim A, Aldridge J, Olszanski AJ. Evofosfamide combined with gemcitabine/nab-paclitaxel in patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma (PAC): Results of a phase I trial. Journal of Clinical Oncology. 34: 4114-4114. DOI: 10.1200/Jco.2016.34.15_Suppl.4114  0.439
2016 Bahary N, Garrido-Laguna I, Cinar P, O'Rourke MA, Somer BG, Nyak-Kapoor A, Lee JS, Munn D, Kennedy EP, Vahanian NN, Link CJ, Wang-Gillam A. Phase 2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreas cancer: Interim analysis. Journal of Clinical Oncology. 34: 3020-3020. DOI: 10.1200/Jco.2016.34.15_Suppl.3020  0.417
2016 Tan BR, Picus J, Chan E, Lockhart AC, Roth BJ, Morton A, Liang C, Wang-Gillam A. Phase I study of X-82, an oral dual anti-VEGFR/PDGFR tyrosine kinase inhibitor, with everolimus in solid tumors. Journal of Clinical Oncology. 34: 2588-2588. DOI: 10.1200/Jco.2016.34.15_Suppl.2588  0.375
2016 Zhang D, Li L, Jiang H, Yu J, Knolhoff B, Head R, Lockhart AC, DeNardo DG, Wang-Gillam A, Ruzinova MB, Lim K. Abstract 181: Constitutive IRAK1/4 kinase activation contributes to NF-kB activity and chemoresistance in pancreatic cancer Cancer Research. 76: 181-181. DOI: 10.1158/1538-7445.Am2016-181  0.408
2016 Hubner R, Chen L, Siveke J, Li C, Bodoky G, Dean A, Shan Y, Jameson G, Macarulla T, Lee K, Cunningham D, Blanc J, Chiu C, Schwartsmann G, Braiteh F, ... ... Wang-Gillam A, et al. Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy Annals of Oncology. 27: vi234. DOI: 10.1093/Annonc/Mdw371.85  0.413
2016 Chen L, Wang-Gillam A, Li C, Bodoky G, Dean A, Shan Y, Jameson G, Macarulla T, Lee K, Cunningham D, Blanc J, Hubner R, Chiu C, Schwartsmann G, Braiteh F, et al. Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy Annals of Oncology. 27: vi211. DOI: 10.1093/Annonc/Mdw371.14  0.417
2016 Melisi D, Melisi D, Siveke J, Blanc J, Von Hoff D, Wang-Gillam A, Chen L, Becker C, Mamlouk K, De Jong F, Hubner R. Effects of nanoliposomal irinotecan (nal-IRI; MM-398) ± 5-fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy: results from the phase 3 NAPOLI-1 study Annals of Oncology. 27: iv18. DOI: 10.1093/Annonc/Mdw333.04  0.38
2016 Chen L, Siveke J, Wang-Gillam A, Hubner R, Pant S, Dragovich T, Chung V, Chang D, Ross P, Cooray P, Tebbutt N, Franke F, Belanger B, Dhindsa N, de Jong F, et al. PD-023 Safety across subgroups in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy Annals of Oncology. 27: ii110. DOI: 10.1093/Annonc/Mdw200.23  0.401
2016 Hubner R, Cubillo A, Blanc J, Melisi D, Von Hoff D, Wang-Gillam A, Chen L, Becker C, Mamlouk K, Belanger B, Yang Y, de Jong F, Siveke J. O-004 Effects of nal-IRI (MM-398) ± 5-fluorouracil on quality of life (QoL) in NAPOLI-1: a phase 3 study in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine Annals of Oncology. 27: ii119. DOI: 10.1093/Annonc/Mdw198.04  0.333
2016 Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, Moorcraft SY, Conroy T, Hohla F, Allen P, Taieb J, et al. FOLFIRINOX for locally advanced pancreatic cancer: A systematic review and patient-level meta-analysis The Lancet Oncology. DOI: 10.1016/S1470-2045(16)00172-8  0.33
2016 Janku F, Murthy R, Wang-Gillam A, Shepard D, Helgason T, Henry T, Rudin C, Huang S, Sakamuri D, Solomon S, Collins A, Kreider B, Miller M, Saha S, Tung D, et al. Phase I clinical study of intratumoral injection of oncolytic Clostridium novyi-NT spores in patients with advanced cancers European Journal of Cancer. 69: S94. DOI: 10.1016/S0959-8049(16)32878-7  0.412
2016 Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes B, Wang-Gillam A, Lacy J, Hosein PJ, Moorcraft SY, Conroy T, Hohla F, Allen P, Taieb J, et al. A patient-level meta-analysis of FOLFIRINOX for locally advanced pancreatic cancer. Pancreatology. 16: S106-S107. DOI: 10.1016/J.Pan.2016.05.358  0.418
2016 Lang GD, Mullady D, Early DS, Hollander T, Edmundowicz S, Murad F, Strasberg SM, Fields R, Hawkins W, Wang-Gillam A, Kushnir V. Su1296 Utility of Endoscopic Ultrasound in Evaluating Local Recurrence After Surgery for Pancreatic Cancer Gastrointestinal Endoscopy. 83. DOI: 10.1016/J.Gie.2016.03.870  0.342
2015 Hayes TK, Neel NF, Hu C, Gautam P, Chenard M, Long B, Aziz M, Kassner M, Bryant KL, Pierobon M, Marayati R, Kher S, George SD, Xu M, Wang-Gillam A, et al. Long-term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. Cancer Cell. PMID 26725216 DOI: 10.1016/J.Ccell.2015.11.011  0.317
2015 Waqar SN, Boehmer L, Morgensztern D, Wang-Gillam A, Sorscher S, Lawrence S, Gao F, Guebert K, Williams K, Govindan R. Immunogenicity of Influenza Vaccination in Patients With Cancer. American Journal of Clinical Oncology. PMID 26669741 DOI: 10.1097/Coc.0000000000000257  0.337
2015 Amin M, Minton SE, LoRusso PM, Krishnamurthi SS, Pickett CA, Lunceford J, Hille D, Mauro D, Stein MN, Wang-Gillam A, Trull L, Lockhart AC. A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors. Investigational New Drugs. PMID 26620496 DOI: 10.1007/S10637-015-0306-7  0.339
2015 Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet (London, England). PMID 26615328 DOI: 10.1016/S0140-6736(15)00986-1  0.455
2015 Du L, DeFoe M, Ruzinova MB, Olsen JR, Wang-Gillam A. Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma. Hematology/Oncology Clinics of North America. 29: 717-26. PMID 26226906 DOI: 10.1016/J.Hoc.2015.04.011  0.463
2015 Pedersen KS, Kim GP, Foster NR, Wang-Gillam A, Erlichman C, McWilliams RR. Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study. Investigational New Drugs. 33: 963-8. PMID 25952464 DOI: 10.1007/S10637-015-0246-2  0.408
2015 Cho M, Wang-Gillam A, Myerson R, Gao F, Strasberg S, Picus J, Sorscher S, Fournier C, Nagaraj G, Parikh P, Suresh R, Linehan D, Tan BR. A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma. Hpb : the Official Journal of the International Hepato Pancreato Biliary Association. 17: 587-93. PMID 25800066 DOI: 10.1111/Hpb.12413  0.375
2015 Teague A, Lim KH, Wang-Gillam A. Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. Therapeutic Advances in Medical Oncology. 7: 68-84. PMID 25755680 DOI: 10.1177/1758834014564775  0.457
2015 Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, Onners B, Uram JN, Laheru DA, Lutz ER, Solt S, et al. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1325-33. PMID 25584002 DOI: 10.1200/Jco.2014.57.4244  0.361
2015 Wang-Gillam A, Williams K. Paving the road to clinical trial participation: removing road blocks and directing patients toward novel therapies. Journal of the National Comprehensive Cancer Network : Jnccn. 13: 118-20. PMID 25583774 DOI: 10.6004/Jnccn.2015.0013  0.446
2015 Chang ST, Nguyen DC, Raptis C, Menias CO, Zhou G, Wang-Gillam A, Linehan DC, Hawkins WG, Strasberg SM, Fields RC. Natural history of preoperative subcentimeter pulmonary nodules in patients with resectable pancreatic adenocarcinoma: a retrospective cohort study. Annals of Surgery. 261: 970-5. PMID 24950261 DOI: 10.1097/Sla.0000000000000719  0.336
2015 Le DT, Wang-Gillam A, Picozzi VJ, Crocenzi TS, Morse M, Zeh H, Fine RL, Murphy A, Skoble J, Lemmens E, Ferber S, Rosen A, Grous JJ, Dubensky T, Brockstedt DG, et al. A phase 2b, randomized, controlled, multicenter, open-label study of the efficacy and immune response of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study) F1000research. 6. DOI: 10.7490/F1000Research.1097494.1  0.344
2015 Olszanski AJ, Wang-Gillam A, Kwak EL, Nazzal K, Mehdi F, Borad MJ. A phase I dose-escalation trial of TH-302 with nab-paclitaxel and gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma. Journal of Clinical Oncology. 33: TPS505-TPS505. DOI: 10.1200/Jco.2015.33.3_Suppl.Tps505  0.399
2015 Le DT, Wang-Gillam A, Picozzi VJ, Crocenzi TS, Morse M, Zeh H, Fine RL, Murphy A, Skoble J, Lemmens E, Ferber S, Rosen A, Grous JJ, Dubensky T, Brockstedt DG, et al. A phase IIb, randomized, controlled, multicenter, open-label study of the efficacy and immune response of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study). Journal of Clinical Oncology. 33: TPS489-TPS489. DOI: 10.1200/Jco.2015.33.3_Suppl.Tps489  0.456
2015 Buchwald ZS, Olsen JR, Badiyan SN, DeWees TA, Hu Y, Fields RC, Wang-Gillam A, Parikh PJ. Pretreatment diffusion weighted imaging for clinical outcome assessment in patients undergoing definitive chemoradiation for pancreatic adenocarcinoma. Journal of Clinical Oncology. 33: 432-432. DOI: 10.1200/Jco.2015.33.3_Suppl.432  0.436
2015 Wang-Gillam A, Nywening TM, Sanford DE, Lockhart AC, Suresh R, Tan BR, Lim K, Sorscher S, Fowler K, Amin MA, Roshal A, Adkins D, Nieman R, Panni RZ, DeNardo DG, et al. Phase IB study of FOLFIRINOX plus PF-04136309 in patients with borderline resectable and locally advanced pancreatic adenocarcinoma (PC). Journal of Clinical Oncology. 33: 338-338. DOI: 10.1200/Jco.2015.33.3_Suppl.338  0.447
2015 Wang-Gillam A, Rimkunas V, Abu-Yousif A, Nywening TM, Gao F, DeNardo DG, Linehan D, Czibere AG, Lugovskoy A. HER3 as a potential prognostic biomarker in pancreatic cancer. Journal of Clinical Oncology. 33: 295-295. DOI: 10.1200/Jco.2015.33.3_Suppl.295  0.444
2015 Chen L, Von Hoff DD, Li C, Wang-Gillam A, Bodoky G, Dean AP, Shan Y, Jameson GS, Macarulla T, Lee K, Cunningham D, Blanc J, Hubner R, Chiu C, Schwartsmann G, et al. Expanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy. Journal of Clinical Oncology. 33: 234-234. DOI: 10.1200/Jco.2015.33.3_Suppl.234  0.409
2015 Lockhart AC, Krajewski KA, Wang-Gillam A, Amin M, Sorscher S, Lim K, Tan BR, Picus J, Hecky A, Allen K, Peterson JD, O'Day E, Marsh RdW, Kozloff M, Polite BN, et al. FOLFIRINOX as first-line therapy in patients with metastatic gastroesophageal cancers (GEC). Journal of Clinical Oncology. 33: 177-177. DOI: 10.1200/Jco.2015.33.3_Suppl.177  0.434
2015 Chung VM, McDonough SL, Philip PA, Cardin DB, Wang-Gillam A, Hui L, Lowy AM, Guthrie K, Blanke CD, Hochster HS. SWOG S1115: Randomized phase II trial of selumetinib (AZD6244; ARRY 142886) hydrogen sulfate (NSC-748727) and MK-2206 (NSC-749607) vs. mFOLFOX in pretreated patients (Pts) with metastatic pancreatic cancer. Journal of Clinical Oncology. 33: 4119-4119. DOI: 10.1200/Jco.2015.33.15_Suppl.4119  0.427
2015 Wang-Gillam A, Tan BR, Waqar SN, Suresh R, Morgensztern D, Van Tine BA, Nieman R, Govindan R, Lockhart AC. A phase I study of temsirolimus plus erlotinib in patients with refractory solid tumors. Journal of Clinical Oncology. 33: 2600-2600. DOI: 10.1200/Jco.2015.33.15_Suppl.2600  0.34
2015 Infante JR, Janku F, Tolcher AW, Patel MR, Sullivan RJ, Flaherty K, Carvajal RD, Varghese AM, Wong DJL, Sznol M, Sosman JA, Wang-Gillam A, Burris HA, Ribas A, Patel SP, et al. Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors. Journal of Clinical Oncology. 33: 2506-2506. DOI: 10.1200/Jco.2015.33.15_Suppl.2506  0.402
2015 Jiang H, Knolhoff B, Zhu Y, Herndon J, Shapiro I, Weaver D, Pachter J, Wang-Gillam A, DeNardo DG. Targeting focal adhesion kinase reprograms the pancreatic tumor microenvironment and renders pancreas cancer responsive to checkpoint immunotherapy Journal For Immunotherapy of Cancer. 3: P400. DOI: 10.1186/2051-1426-3-S2-P400  0.378
2015 Xu M, Lockhart AC, Myerson RJ, Zoberi I, Linette GP, Wang-Gillam A. Abstract B14: A novel strategy for the treatment of melanoma Cancer Research. 75. DOI: 10.1158/1538-7445.Mel2014-B14  0.347
2015 Hezel A, Eskens F, Sleijfer S, Noel M, Wang-Gillam A, Cheng S, Potarca A, Zhao B, Lohr L, Miao S, Charo I, Bekker P, Schall TJ. Abstract B24: Pharmacokinetic and pharmacodynamic profile of the novel, oral and selective CCR2 inhibitor CCX872-B in a Phase 1B pancreatic cancer trial Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B24  0.423
2014 Goff LW, Thakkar N, Du L, Chan E, Tan BR, Cardin DB, McLeod HL, Berlin JD, Zehnbauer B, Fournier C, Picus J, Wang-Gillam A, Lee W, Lockhart AC. Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers. Plos One. 9: e107424. PMID 25232828 DOI: 10.1371/Journal.Pone.0107424  0.381
2014 Lockhart AC, Sundaram S, Sarantopoulos J, Mita MM, Wang-Gillam A, Moseley JL, Barber SL, Lane AR, Wack C, Kassalow L, Dedieu JF, Mita AC. Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors. Investigational New Drugs. 32: 1236-45. PMID 25117475 DOI: 10.1007/S10637-014-0145-Y  0.368
2014 Wang-Gillam A, Thakkar N, Lockhart AC, Williams K, Baggstrom M, Naughton M, Suresh R, Ma C, Tan B, Lee W, Jiang X, Mwandoro T, Trull L, Belanger S, Creekmore AN, et al. A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies. Cancer Chemotherapy and Pharmacology. 74: 419-26. PMID 24916546 DOI: 10.1007/S00280-014-2493-X  0.421
2014 Panni RZ, Sanford DE, Belt BA, Mitchem JB, Worley LA, Goetz BD, Mukherjee P, Wang-Gillam A, Link DC, Denardo DG, Goedegebuure SP, Linehan DC. Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer. Cancer Immunology, Immunotherapy : Cii. 63: 513-28. PMID 24652403 DOI: 10.1007/S00262-014-1527-X  0.335
2014 Myerson RJ, Tan B, Hunt S, Olsen J, Birnbaum E, Fleshman J, Gao F, Hall L, Kodner I, Lockhart AC, Mutch M, Naughton M, Picus J, Rigden C, Safar B, ... ... Wang-Gillam A, et al. Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer. International Journal of Radiation Oncology, Biology, Physics. 88: 829-36. PMID 24606849 DOI: 10.1016/J.Ijrobp.2013.12.028  0.368
2014 Wang-Gillam A, Picozzi V, Crocenzi T, Morse M, Zeh H, Fine RL, Murphy A, Skoble J, Lemmens E, Ferber S, Rosen A, Grous J, Dubensky T, Brockstedt D, Jaffee E, et al. A Phase IIb, randomized, multicenter study of the efficacy of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone... Journal For Immunotherapy of Cancer. 2: 68. DOI: 10.7916/D8X63Kk8  0.427
2014 Lim K, Lockhart AC, Waqar SN, Govindan R, Baggstrom MQ, Wang-Gillam A. Phase I study combining MLN8237 with nab-paclitaxel in patients with advanced solid malignancies. Journal of Clinical Oncology. 32: TPS2644-TPS2644. DOI: 10.1200/Jco.2017.35.15_Suppl.2553  0.445
2014 Tan BR, Wu N, Wang-Gillam A, Suresh R, Picus J, Baranda JC, Lockhart AC, McLeod HL. Final results of the UGT1A1-based dose modification of irinotecan and its impact on rates of severe neutropenia and hospitalization. Journal of Clinical Oncology. 32: 461-461. DOI: 10.1200/Jco.2014.32.3_Suppl.461  0.383
2014 Cho M, Wang-Gillam A, Gao F, Linehan D, Hawkins WG, Suresh R, Fournier C, Picus J, Tan B. Adjuvant gemcitabine plus docetaxel followed by 5FU chemoradiation for patients with resected pancreaticobiliary cancers: A single institution phase II study. Journal of Clinical Oncology. 32: 325-325. DOI: 10.1200/Jco.2014.32.3_Suppl.325  0.494
2014 Keller JW, Doyle MM, Wang-Gillam A, Brunt E, Vachhajarani N, Chapman W, Tan BR. Analysis of the genomic profile of biphenotypic tumors compared to cholangiocarcinoma and hepatocellular carcinoma. Journal of Clinical Oncology. 32: 226-226. DOI: 10.1200/Jco.2014.32.3_Suppl.226  0.324
2014 Teague AS, Tan BR, Lockhart AC, Picus J, Strasberg SM, Hawkins WG, Fields RC, Linehan D, Wang-Gillam A. Next-generation sequencing in pancreatic cancer: Revealing genomic mutations beyond KRAS. Journal of Clinical Oncology. 32: 208-208. DOI: 10.1200/Jco.2014.32.3_Suppl.208  0.329
2014 Le DT, Wang-Gillam A, Picozzi, Jr V, Greten TF, Crocenzi TS, Springett GM, Morse M, Zeh H, Cohen DJ, Fine RL, Onners B, Uram JN, Laheru D, Murphy A, et al. A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: Updated results. Journal of Clinical Oncology. 32: 177-177. DOI: 10.1200/Jco.2014.32.3_Suppl.177  0.441
2014 Teague AS, Tan BR, Picus J, Lockhart AC, Sorscher S, Suresh R, Strasberg SM, Hawkins WG, Fields RC, Linehan D, Bredemeyer A, Cottrell CE, Wang-Gillam A. Next-generation sequencing in pancreatic cancer: Novel mutations and potential targets for therapy. Journal of Clinical Oncology. 32: e15228-e15228. DOI: 10.1200/Jco.2014.32.15_Suppl.E15228  0.37
2014 Wang-Gillam A, Picozzi V, Crocenzi T, Morse M, Zeh H, Fine R, Murphy A, Skoble J, Lemmens E, Ferber S, Rosen A, Grous J, Dubensky TW, Brockstedt D, Jaffee E, et al. A Phase IIb, randomized, multicenter study of the efficacy of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously-treated metastatic pancreatic adenocarcinoma (eclipse study) Journal For Immunotherapy of Cancer. 2: P68. DOI: 10.1186/2051-1426-2-S3-P68  0.363
2014 Lockhart AC, Liu Y, Dehdashti F, Laforest R, Picus J, Wang-Gillam A, Trull L, Belanger S, Desai M, Mendell J, Mahmood S, Siegel BA, Welch MJ. Abstract 5443: A phase 1 evaluation of64Cu-DOTA-patritumab to assess dosimetry, receptor occupancy, and safety in advanced solid tumors Cancer Research. 74: 5443-5443. DOI: 10.1158/1538-7445.Am2014-5443  0.315
2014 Von Hoff D, Li C, Wang-Gillam A, Bodoky G, Dean A, Jameson G, Macarulla T, Lee K, Cunningham D, Blanc J, Hubner R, Chiu C, Schwartsmann G, Siveke J, Braiteh F, et al. NAPOLI-1: Randomized Phase 3 Study of MM-398 (NAL-IRI), with or Without 5-Fluorouracil and Leucovorin, Versus 5-Fluorouracil and Leucovorin, in Metastatic Pancreatic Cancer Progressed on or Following Gemcitabine-Based Therapy Annals of Oncology. 25: ii105. DOI: 10.1093/Annonc/Mdu193.3  0.466
2013 Badiyan SN, Olsen JR, Lee AY, Yano M, Menias CO, Khwaja S, Wang-Gillam A, Strasberg SM, Hawkins WG, Linehan DC, Myerson RJ, Parikh PJ. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. American Journal of Clinical Oncology. PMID 26132367 DOI: 10.1097/Coc.0000000000000003  0.399
2013 Peddi PF, Cho M, Wang J, Gao F, Wang-Gillam A. Nab-paclitaxel monotherapy in refractory pancreatic adenocarcinoma. Journal of Gastrointestinal Oncology. 4: 370-3. PMID 24294508 DOI: 10.1016/J.Pan.2012.12.283  0.444
2013 Zhong H, Sanchez C, Spitrzer D, Plambeck-Suess S, Gibbs J, Hawkins WG, Denardo D, Gao F, Pufahl RA, Lockhart AC, Xu M, Linehan D, Weber J, Wang-Gillam A. Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models. Plos One. 8: e77243. PMID 24130864 DOI: 10.1371/Journal.Pone.0077243  0.398
2013 Sanford DE, Porembka MR, Panni RZ, Mitchem JB, Belt BA, Plambeck-Suess SM, Lin G, Denardo DG, Fields RC, Hawkins WG, Strasberg SM, Lockhart AC, Wang-Gillam A, Goedegebuure SP, Linehan DC. A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Journal of Cancer Therapy. 4: 797-803. PMID 24089656 DOI: 10.4236/Jct.2013.43096  0.447
2013 Sanford DE, Belt BA, Panni RZ, Mayer A, Deshpande AD, Carpenter D, Mitchem JB, Plambeck-Suess SM, Worley LA, Goetz BD, Wang-Gillam A, Eberlein TJ, Denardo DG, Goedegebuure SP, Linehan DC. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3404-15. PMID 23653148 DOI: 10.1158/1078-0432.Ccr-13-0525  0.356
2013 Tempero MA, Klimstra D, Berlin J, Hollingsworth T, Kim P, Merchant N, Moore M, Pleskow D, Wang-Gillam A, Lowy AM. Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 538-40. PMID 23344262 DOI: 10.1158/1078-0432.Ccr-12-2745  0.385
2013 Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, Belaygorod L, Carpenter D, Collins L, Piwnica-Worms D, Hewitt S, Udupi GM, Gallagher WM, Wegner C, West BL, ... Wang-Gillam A, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Research. 73: 1128-41. PMID 23221383 DOI: 10.1158/0008-5472.Can-12-2731  0.333
2013 Wang-Gillam A, Plambeck-Suess S, Goedegebuure P, Simon PO, Mitchem JB, Hornick JR, Sorscher S, Picus J, Suresh R, Lockhart AC, Tan B, Hawkins WG. A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. Investigational New Drugs. 31: 707-13. PMID 22864469 DOI: 10.1007/S10637-012-9866-Y  0.438
2013 Wang-Gillam A, Abrams RA, Posner MC, Pisters PW, Picozzi VJ. Supportive care considerations during concurrent chemoradiotherapy for pancreatic adenocarcinoma: lessons learned from clinical experience. American Journal of Clinical Oncology. 36: 637-43. PMID 22237148 DOI: 10.1097/Coc.0B013E31823A53Ce  0.433
2013 McWilliams RR, Foster NR, Wang-Gillam A, Erlichman C, Kim GP. Phase II consortium (P2C) study of gemcitabine and tanespimycin (17AAG) for metastatic pancreatic cancer. Journal of Clinical Oncology. 31: 245-245. DOI: 10.1200/Jco.2013.31.4_Suppl.245  0.48
2013 Wang-Gillam A, Wani S, Langley EJ, Gao F, Murad F, Mullady D, Early DS, Edmundowicz SA, Linehan D, Kuller A, Jain A, Kim PS, Singh S, Azar R. Identifying targetable pathways in pancreatic cancer from endoscopic ultrasound-guided fine-needle aspirates (EUS/FNA): Providing a personalized approach to targeted therapy. Journal of Clinical Oncology. 31: 4051-4051. DOI: 10.1200/Jco.2013.31.15_Suppl.4051  0.425
2013 Le DT, Wang-Gillam A, Picozzi VJ, Greten TF, Crocenzi TS, Springett GM, Morse M, Zeh H, Cohen DJ, Fine RL, Onners B, Uram JN, Murphy A, Skoble J, Lemmens E, et al. Interim safety and efficacy analysis of a phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer. Journal of Clinical Oncology. 31: 4040-4040. DOI: 10.1200/Jco.2013.31.15_Suppl.4040  0.479
2013 Mitchem JB, Brennan DJ, Sanford DE, Knolhoff BL, Zhu Y, Brian B, Wang-Gillam A, Goedegebuure P, Linehan DC, DeNardo DG. Abstract B83: Targeting tumor-infiltrating macrophages decreases pancreatic tumor-initiating cells and improves chemotherapeutic responses by relieving immune suppression. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-B83  0.343
2013 Lockhart AC, Olszanski AJ, Allgren RL, Yaguchi S, Cohen SJ, Hilton JF, Wang-Gillam A, Shapiro GI. Abstract B271: A first-in-human Phase I study of ZSTK474, an oral pan-PI3K inhibitor, in patients with advanced solid malignancies. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B271  0.429
2013 Wang-Gillam A. How Do I Treat Patients with Metastatic Pancreatic Adenocarcinoma? Oncology Times. 35: 15-16. DOI: 10.1097/01.COT.0000430602.85911.fd  0.31
2012 Myerson RJ, Parikh PJ, Tan B, Hunt S, Fleshman JW, Birnbaum EH, Mutch MG, Kodner IJ, Safar B, Naughton M, Picus J, Sorscher S, Lockhart AC, Rigden C, Suresh R, ... Wang-Gillam A, et al. A single-institution phase II trial of five fractions of radiotherapy followed by four courses of FOLFOX chemotherapy as preoperative therapy for rectal adenocarcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 553. PMID 27983288 DOI: 10.1200/Jco.2012.30.4_Suppl.553  0.347
2012 Peddi PF, Tan BR, Picus J, Sorscher S, Suresh R, Lockhart AC, Menias C, Linehan D, Wang-Gillam A. Washington University experience with FOLFIRINOX in pancreatic cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 354. PMID 27983098 DOI: 10.1200/Jco.2012.30.4_Suppl.354  0.471
2012 Wang-Gillam A, Ding K, Cho M, Lockhart AC, Chen L, Zubal B, Tan B. Vitamin D deficiency in patients with pancreatic cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 353. PMID 27983089 DOI: 10.1200/Jco.2012.30.4_Suppl.353  0.334
2012 Peddi PF, Wang-Gillam A. Successful resection after neoadjuvant therapy in pancreatic adenocarcinoma. Journal of the National Comprehensive Cancer Network : Jnccn. 10: 1330-4. PMID 23138162 DOI: 10.6004/Jnccn.2012.0139  0.378
2012 Peddi PF, Lubner S, McWilliams R, Tan BR, Picus J, Sorscher SM, Suresh R, Lockhart AC, Wang J, Menias C, Gao F, Linehan D, Wang-Gillam A. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. Jop : Journal of the Pancreas. 13: 497-501. PMID 22964956 DOI: 10.6092/1590-8577/913  0.416
2012 Lim KH, Chung E, Khan A, Cao D, Linehan D, Ben-Josef E, Wang-Gillam A. Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? The Oncologist. 17: 192-200. PMID 22250057 DOI: 10.1634/Theoncologist.2011-0268  0.42
2012 Wang-Gillam A, Tew WP, Rothenberg ML, Dupont J, Cooper W, Sternas L, Buzenet G, Sosman JA, Spriggs DR, Lockhart AC. A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors. Investigational New Drugs. 30: 1958-61. PMID 22002018 DOI: 10.1007/S10637-011-9753-Y  0.371
2012 Wang-Gillam A, Arnold SM, Bukowski RM, Rothenberg ML, Cooper W, Wang KK, Gauthier E, Lockhart AC. A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors. Investigational New Drugs. 30: 266-72. PMID 20697774 DOI: 10.1007/S10637-010-9506-3  0.38
2012 Wang-Gillam A, Wani S, Early DS, Edmundowicz SA, Mullady D, Murad F, Jonnalagadda S, Gao F, Hollander T, Langley EJ, Meyer G, Singh S, Kim PS, Lim K, Linehan D, et al. A pilot study of evaluation of a phosphorylation signature from pancreatic cancer tumors. Journal of Clinical Oncology. 30: e14584-e14584. DOI: 10.1200/Jco.2012.30.15_Suppl.E14584  0.393
2012 Wani S, Wang-Gillam A, Early DS, Kim P, Mullady D, Murad F, Langley E, Kuller A, Hollander TG, Kohlmeier C, Singh S, Edmundowicz SA, Azar RR. Su1909 Evaluation of Phosphorylation Signatures in Suspected Pancreatic Cancer Using Endoscopic Ultrasound-Guided Fine Needle (EUS-FNA) Aspirates: A Feasibility Study Gastroenterology. 142: S-533. DOI: 10.1016/S0016-5085(12)62048-4  0.345
2012 Wani S, Wang-Gillam A, Early DS, Kim P, Mullady D, Murad F, Langley E, Kohlmeier C, Singh S, Kuller A, Hollander TG, Edmundowicz SA, Azar RR. Sa1520 Comparison of Phosphorylation Signatures in Patients With Suspected Pancreatic Cancer Undergoing Endoscopic Ultrasound-Fine Needle (EUS-FNA) With and Without Malignant Cytology: A Pilot Study Gastrointestinal Endoscopy. 75: AB189-AB190. DOI: 10.1016/J.Gie.2012.04.309  0.391
2011 Myerson RJ, Hunt SR, Tan BR, Parikh P, Lockhart AC, Picus J, Sorscher S, Suresh R, Wang-Gillam A, Fleshman JW, Kodner IJ. Phase II trial of five fractions of radiotherapy followed by four cycles of FOLFOX chemotherapy as preoperative therapy for rectal adenocarcinoma: Report of an interim response analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e14003. PMID 28022542 DOI: 10.1200/Jco.2011.29.15_Suppl.E14003  0.355
2011 Dandona M, Linehan D, Hawkins W, Strasberg S, Gao F, Wang-Gillam A. Influence of obesity and other risk factors on survival outcomes in patients undergoing pancreaticoduodenectomy for pancreatic cancer. Pancreas. 40: 931-7. PMID 21747317 DOI: 10.1097/Mpa.0B013E318215A9B1  0.343
2011 Goedegebuure P, Mitchem JB, Porembka MR, Tan MCB, Belt BA, Wang-Gillam A, Gillanders WE, Hawkins WG, Linehan DC. Myeloid-derived suppressor cells: General characteristics and relevance to clinical management of pancreatic cancer Current Cancer Drug Targets. 11: 734-751. PMID 21599634 DOI: 10.2174/156800911796191024  0.405
2011 Castleton K, Fong T, Wang-Gillam A, Waqar MA, Jeffe DB, Kehlenbrink L, Gao F, Govindan R. A survey of Internet utilization among patients with cancer. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 19: 1183-90. PMID 20556435 DOI: 10.1007/S00520-010-0935-5  0.329
2010 Wang-Gillam A, Williams K, Novello S, Gao F, Scagliotti GV, Govindan R. Time to activate lung cancer clinical trials and patient enrollment: a representative comparison study between two academic centers across the atlantic. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 3803-7. PMID 20644091 DOI: 10.1200/Jco.2010.28.1824  0.342
2010 Dandona M, Gao F, Linehan DC, Wang-Gillam A. Re: ABO blood group and the risk of pancreatic cancer. Journal of the National Cancer Institute. 102: 135-7; author reply . PMID 20019335 DOI: 10.1093/Jnci/Djp447  0.307
2010 Abboud R, Pai R, Picus J, Hall-Daniels LE, Suresh R, Wang-Gillam A, Sorscher S, Tan BR. Demographic factors on the incidence of KRAS mutation in colorectal cancers. Journal of Clinical Oncology. 28: e14040-e14040. DOI: 10.1200/Jco.2010.28.15_Suppl.E14040  0.325
2010 Mwandoro TN, Gao F, Lockhart AC, Suresh R, Tan BR, Wang-Gillam A, Fracasso PM, Picus J. Phase I study of docetaxel and temsirolimus in refractory solid tumors. Journal of Clinical Oncology. 28: e13149-e13149. DOI: 10.1200/Jco.2010.28.15_Suppl.E13149  0.32
2009 Wang-Gillam A, Novello S, Williams K, Gao F, Scagliotti GV, Govindan R. An international comparison of barriers in opening oncology clinical trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 6580. PMID 27963821 DOI: 10.1200/Jco.2009.27.15_Suppl.6580  0.348
2008 Martin MG, Wang-Gillam A, Waqar MA, Fong TH, Gao F, Govindan R, Morgensztern D. Second-line systemic therapy for esophageal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 15623. PMID 27951158 DOI: 10.1200/Jco.2008.26.15_Suppl.15623  0.413
2000 Wang-Gillam A, Pastuszak I, Stewart M, Drake RR, Elbein AD. Identification and modification of the uridine-binding site of the UDP-GalNAc (GlcNAc) pyrophosphorylase. The Journal of Biological Chemistry. 275: 1433-8. PMID 10625695 DOI: 10.1074/Jbc.275.2.1433  0.478
1998 Wang-Gillam A, Pastuszak I, Elbein AD. A 17-amino acid insert changes UDP-N-acetylhexosamine pyrophosphorylase specificity from UDP-GalNAc to UDP-GlcNAc. The Journal of Biological Chemistry. 273: 27055-7. PMID 9765219 DOI: 10.1074/Jbc.273.42.27055  0.476
Show low-probability matches.